(EMAILWIRE.COM, December 18, 2019 ) Market Overview
• Von Willebrand disease (vWD) is a common genetic hemorrhagic disorder caused by a deficiency or dysfunction of the protein termed von Willebrand factor (vWF). VWF binds factor VIII, a key clotting protein, and platelets in blood vessel walls, which help form a platelet plug during the clotting process. There are many treatment options available for patients with von Willebrand disease including hormonal and non-hormonal therapies.
• The global Von Willebrand Disease Treatment market size was worth $ YY billion in 2018 and is forecasted to reach $ YY billion by 2026, at a CAGR of YY% during the forecast period (2019-2026).

Download free sample: https://www.datamintelligence.com/download-sample/von-willebrand-disease-treatment-market

Market Dynamics
The Von Willebrand Disease (VWD) Treatment Market is growing due to rising prevalence of von Willebrand disease globally. In 2019, the PWD is estimated to affect approximately 1% of the general population, however, clinically significant disease prevalence is estimated to be about 125 per million, with severe disease affecting up to five per million. This disease has an equal distribution among males and females. The acquired von Willebrand disease prevalence represents about 1% to 5% of all von Willebrand disease. Its prevalence is higher in certain groups. For instance, it has been reported up to 20% of malignancies, and up to 100% of certain high flow states such as extracorporeal membrane oxygenation (ECMO) and metallic cardiac valves. According to the World Federation of Hemophilia’s annual global survey, which is conducted every year, in 2017, 76,144 people were affected by von Willebrand disease (vWD) worldwide.

In addition, rising awareness towards von Willebrand disease (VWD) and increasing patient assistance programs are also driving the growth of the market. Von Willebrand disease (VWD) is a rare hereditary which may not be diagnosed and requires awareness in patient assistance programs. Several organizations and companies are focusing on increasing awareness among people about von Willebrand disease. For instance, the American Society of Hematology (ASH) takes several initiatives such as establishment of the clinical research training institute in Latin America, implementation of global research award and visitor training program which are expected to boost the growth of the market during the forecast period (2019-2026).

However, the high cost of treatment is one of the major challenges for patients with von Willebrand disease (VWD). The cost of investments for drug development is high as due to the rarity and distinctive treatment approach for this disease. The drugs for von Willebrand disease treatment are synthetic in nature, and the cost of recombinant therapy is higher. Hence, high cost is one of the major factor hindering the growth of the market.

Market Segmentation
• On the basis of disease type, the von Willebrand disease (vWD) treatment market is segmented into Type 1 vWD, Type 2 vWD, Type 3 vWD, and Acquired vWD. Among these, the type 1 von Willebrand disease segment accounted for the largest market share in 2018, owing to the increasing number of Type 1 vWD cases and new product development. The increase in the patient pool for Type 1 vWD accounts for 60% to 80% of the patients with vWD which drives the growth of this segment. A person with Type 1 vWD also might have low levels of factor VIII, another type of blood-clotting protein. About 85% of people treated for VWD have Type 1. The Type 1 von Willebrand disease is treated by desmopressin, a synthetic hormone which allows the Von Willebrand factor in the blood vessels lining to be released. Type 1 and Type 2 of Von Willebrand disease have more effective results with this type of Willebrand Disease treatment as compared to the other types.
• Based on drug type, the global von Willebrand disease (vWD) treatment market is segmented into clot-stabilizing medications, desmopressin, contraceptives, replacement therapies, fibrin sealants, and others. Among these, the desmopressin segment held the major share in 2018, owing to better effectiveness in the treatment of the disease compared to others. Desmopressin acetate Injection (DDAVP®), is a medicine that injected into a vein to treat people with milder forms of VWD (mainly type 1). It works by making the body release more VWF into the blood. It helps increase the level of factor VIII in the blood as well.
• If desmopressin is not effective then the von Willebrand disease (vWD) is treated with replacement therapies. Several other therapies are being introduced which reduces the risk of allergic conditions or viral infection. For women facing heavy menstrual flow, contraceptives are provided as a treatment option. Other clot-stabilizing drugs help mainly in dental procedures by slowing down the breakdown of blood clots.

Geographical Analysis
• North America is dominating the global von Willebrand disease treatment market accounting for largest market share in 2018, owing to the rising prevalence von Willebrand disease (vWD), increase in patient assistance programs and the introduction of gene therapy. VWD is the most common bleeding disorder, found in up to 1% of the U.S. population, i.e. 3.2 million (or about 1 in every 100) people in the United States have the disease. In this region, the healthcare sector continues to evolve and a positive growth has been observed in drug discovery and development.
• In addition, rising technological advancements are driving the drug development in terms of von Willebrand disease treatment to offer better disease management to patients.
• Several organizations, key players are adopting various strategies such as merger, collaborations, product launches to generate awareness, and develop clinical practices on the diagnosis and treatment of the disease. For instance, in 2016, VONVENDI® was launched in the U.S. as the first and only recombinant von Willebrand factor for the on-demand treatment of the rare bleeding disorder von Willebrand disease (VWD) in adult patients. However, the healthcare professionals (HCPs) were unfamiliar with VONVENDI® and were more used to the established VWF replacement therapies, and guidelines, which reinforced the status quo.
• For instance, in June 2018, the American Society of Hematology (ASH) collaborated with the International Society on Thrombosis and Haemostasis (ISTH), National Hemophilia Foundation (NHF), World Federation of Hemophilia (WFH), and the University of Kansas Medical Center to develop clinical practice guidelines on the diagnosis and management of von Willebrand Disease (VWD).
• The Asia-Pacific von Willebrand disease treatment market are expected to growt at a significant CAGR during the forecast period (2019-2026), owing to rising cases of von Willebrand disease, increasing initiatives by governments for healthcare access in developing countries. According to Hemophilia Federation India, there were about 20727 people with Hemophilia in India (31st March 2018) of which 81% is Hemophilia A, 12% is Hemophilia B and about 3% is attributable to von Willebrand disease (VWD).
• In May 2019, the Indian Council of Medical Research (ICMR) has developed an affordable test kit for diagnosis of common blood disorders such as severe Haemophilia A and von Willebrand disease (VWD). According to the ICMR scientists, the diagnosis can be done within 30 minutes of blood sample collection.

Competitive Landscape
• The Von Willebrand Disease Treatment market is highly competitive with presence of large number of players including Grifols, S.A., Octapharma AG, Baxter, Shire plc, Bayer AG, Novo Nordisk A/S, Pfizer, CSL Behring, Sanofi, and Ferring B.V.
• The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations which are contributing to the growth of the Von Willebrand Disease Treatment market globally. For instance,
• In September 2018, Shire plc received the European Commission (EC) approval for marketing authorization of VEYVONDI, for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease (VWD) when desmopressin (DDAVP) treatment alone is ineffective or not indicated.

View full report: https://www.datamintelligence.com/research-report/von-willebrand-disease-treatment-market

Enquiry before buying: https://www.datamintelligence.com/enquiry/von-willebrand-disease-treatment-market


Related Reports:
Wilsons Disease Treatment Market

About Us
DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.

For more information:
Sai Kiran
Sales Manager at Data M Intelligence
Email: info@datamintelligence.com
Tel: +1 877 441 4866
Website: www.datamintelligence.com

Contact Information:
DataM Intelligence
Sai Kiran
Tel: +1 877 441 4866
Email us


----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results